Free Trial
→ This Cold War “Accident” Could Unleash New $100 Trillion AI Boom (From Brownstone Research) (Ad) Free SANA Stock Alerts

Sana Biotechnology (SANA) Financials

Sana Biotechnology logo
$4.28 +0.11 (+2.51%)
As of 11:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Sana Biotechnology

Annual Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -131 -285 -356 -269 -283 -267
Consolidated Net Income / (Loss)		 -131 -285 -356 -269 -283 -267
Net Income / (Loss) Continuing Operations		 -131 -285 -356 -269 -283 -267
Total Pre-Tax Income 		-138 -285 -356 -269 -283 -267
Total Operating Income		 -141 -286 -357 -273 -293 -273
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 141 286 357 273 293 273
Selling, General & Admin Expense		 22 28 50 72 73 64
Research & Development Expense		 119 258 306 201 220 209
Total Other Income / (Expense), net		 2.83 0.84 0.98 3.09 9.89 5.96
Interest & Investment Income		 2.86 0.75 0.68 3.76 9.94 10
Other Income / (Expense), net		 -0.03 0.10 0.31 -0.67 -0.05 -4.51
Basic Earnings per Share		 ($26.68) ($21.92) ($2.14) ($1.43) ($1.46) ($1.16)
Weighted Average Basic Shares Outstanding		 4.90M 13.01M 166.43M 188.34M 194.54M 230.89M
Diluted Earnings per Share		 ($26.68) ($21.92) ($2.14) ($1.43) ($1.46) ($1.16)
Weighted Average Diluted Shares Outstanding		 4.90M 13.01M 166.43M 188.34M 194.54M 230.89M
Weighted Average Basic & Diluted Shares Outstanding		 4.90M 13.01M 166.43M 191.36M 220.45M 225.02M

Quarterly Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -85 -80 -82 -114 0.98 -88 -107 -50 -60 -49 -49
Consolidated Net Income / (Loss)		 -85 -80 -82 -114 0.98 -88 -107 -50 -60 -49 -49
Net Income / (Loss) Continuing Operations		 -85 -80 -82 -114 0.98 -88 -107 -50 -60 -49 -49
Total Pre-Tax Income 		-85 -80 -82 -114 0.98 -88 -108 -50 -60 -49 -49
Total Operating Income		 -86 -82 -84 -116 -2.18 -91 -111 -49 -62 -51 -51
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 86 82 84 116 2.18 91 111 49 62 51 51
Selling, General & Admin Expense		 16 23 17 17 19 21 16 16 14 17 11
Research & Development Expense		 71 58 67 100 -17 70 94 33 48 34 39
Total Other Income / (Expense), net		 1.07 1.35 1.98 2.29 3.17 2.46 3.03 -0.92 1.84 1.80 1.24
Interest & Investment Income		 1.17 1.61 1.98 2.37 2.86 2.73 3.03 3.20 2.58 1.66 0.99
Other Income / (Expense), net		 -0.11 -0.27 - -0.08 0.30 - - -4.12 -0.74 0.14 0.25
Basic Earnings per Share		 ($0.45) ($0.42) ($0.43) ($0.59) $0.00 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21)
Weighted Average Basic Shares Outstanding		 189.30M 188.34M 191.23M 192.54M 196.98M 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M
Diluted Earnings per Share		 ($0.45) ($0.42) ($0.43) ($0.59) $0.00 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21)
Weighted Average Diluted Shares Outstanding		 189.30M 188.34M 191.23M 192.54M 200.47M 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M
Weighted Average Basic & Diluted Shares Outstanding		 190.73M 191.36M 191.50M 196.94M 197.13M 220.45M 221.50M 222.47M 223.27M 225.02M 225.56M

Annual Cash Flow Statements for Sana Biotechnology

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 50 45 135 -75 -50 -5.95
Net Cash From Operating Activities		 -86 -138 -251 -290 -254 -223
Net Cash From Continuing Operating Activities		 -86 -138 -251 -290 -254 -223
Net Income / (Loss) Continuing Operations		 -131 -285 -356 -269 -283 -267
Consolidated Net Income / (Loss)		 -131 -285 -356 -269 -283 -267
Depreciation Expense		 1.83 5.92 11 16 25 17
Non-Cash Adjustments To Reconcile Net Income		 21 10 26 41 35 36
Changes in Operating Assets and Liabilities, net		 23 131 68 -77 -30 -10
Net Cash From Investing Activities		 -88 -253 -246 211 172 17
Net Cash From Continuing Investing Activities		 -88 -253 -246 211 172 17
Purchase of Property, Plant & Equipment		 -26 -24 -30 -21 -20 -33
Purchase of Investments		 -142 -387 -491 -79 -158 -226
Sale and/or Maturity of Investments		 83 159 280 310 350 277
Other Investing Activities, net		 0.00 0.00 -4.57 0.00 0.00 0.00
Net Cash From Financing Activities		 224 436 632 4.91 32 200
Net Cash From Continuing Financing Activities		 224 436 632 4.91 32 200
Issuance of Common Equity		 0.00 0.00 632 4.91 32 192
Other Financing Activities, net		 0.00 0.15 0.00 0.00 0.00 7.74

Quarterly Cash Flow Statements for Sana Biotechnology

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -31 13 -16 13 -12 -35 44 -42 -7.96 0.57 -31
Net Cash From Operating Activities		 -65 -76 -79 -59 -64 -52 -66 -59 -52 -47 -49
Net Cash From Continuing Operating Activities		 -65 -76 -79 -59 -64 -52 -66 -59 -52 -47 -49
Net Income / (Loss) Continuing Operations		 -85 -80 -82 -114 0.98 -88 -107 -50 -60 -49 -49
Consolidated Net Income / (Loss)		 -85 -80 -82 -114 0.98 -88 -107 -50 -60 -49 -49
Depreciation Expense		 4.02 4.20 4.35 4.45 4.50 11 3.75 3.90 4.06 5.69 3.65
Non-Cash Adjustments To Reconcile Net Income		 10 11 9.19 10 8.41 7.82 13 13 9.89 5.39 5.98
Changes in Operating Assets and Liabilities, net		 6.01 -11 -11 41 -77 17 25 -26 -5.84 -9.18 -8.90
Net Cash From Investing Activities		 32 88 63 43 51 15 -77 5.82 42 47 17
Net Cash From Continuing Investing Activities		 32 88 63 43 51 15 -77 5.82 42 47 17
Purchase of Property, Plant & Equipment		 -4.35 -4.60 -2.18 -1.58 -2.23 -14 -16 -13 -4.09 -0.44 -0.14
Purchase of Investments		 -18 -15 -20 -51 -60 -26 -114 -63 -36 -13 -1.68
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.25
Sale and/or Maturity of Investments		 54 108 85 95 114 55 53 81 82 61 18
Net Cash From Financing Activities		 1.62 1.06 0.24 30 0.19 1.72 186 11 2.08 0.64 0.98
Net Cash From Continuing Financing Activities		 1.62 1.06 0.24 30 0.19 1.72 186 11 2.08 0.64 1.13
Issuance of Common Equity		 1.62 1.06 0.24 30 0.19 1.72 186 3.00 1.91 0.70 1.13

Annual Balance Sheets for Sana Biotechnology

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 730 1,129 823 565 501
Total Current Assets		 384 558 444 214 161
Cash & Equivalents		 125 253 177 134 128
Restricted Cash		 - 0.00 6.10 3.83 3.83
Short-Term Investments		 253 298 247 72 25
Prepaid Expenses		 6.20 7.11 14 4.49 4.48
Plant, Property, & Equipment, net		 47 65 67 71 77
Total Noncurrent Assets		 299 506 311 281 263
Long-Term Investments		 34 205 10 0.00 0.00
Goodwill		 141 141 141 141 141
Intangible Assets		 59 59 59 59 59
Other Noncurrent Operating Assets		 66 101 101 81 63
Total Liabilities & Shareholders' Equity		 730 1,129 823 565 501
Total Liabilities		 299 401 323 278 251
Total Current Liabilities		 31 99 112 64 45
Short-Term Debt		 - 51 55 0.00 0.00
Accounts Payable		 2.25 2.22 2.86 4.11 5.21
Accrued Expenses		 9.47 10 15 23 13
Current Employee Benefit Liabilities		 16 21 26 24 14
Other Current Liabilities		 3.71 14 12 13 13
Total Noncurrent Liabilities		 267 302 212 213 205
Capital Lease Obligations		 - 102 96 91 82
Other Noncurrent Operating Liabilities		 267 200 116 122 123
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -421 729 499 288 251
Total Preferred & Common Equity		 -421 729 499 288 251
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -421 729 499 288 251
Common Stock		 8.22 1,515 1,558 1,626 1,855
Retained Earnings		 -429 -785 -1,055 -1,338 -1,605
Accumulated Other Comprehensive Income / (Loss)		 0.03 -1.37 -4.33 -0.06 0.01

Quarterly Balance Sheets for Sana Biotechnology

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 898 747 707 631 681 619 559 445
Total Current Assets		 500 370 339 280 321 263 210 113
Cash & Equivalents		 163 160 174 168 177 135 127 96
Restricted Cash		 6.10 6.10 6.10 3.83 3.83 3.83 3.83 4.20
Short-Term Investments		 322 189 152 100 134 117 72 8.57
Prepaid Expenses		 8.40 15 6.61 7.12 6.35 7.98 7.31 3.84
Plant, Property, & Equipment, net		 67 64 63 68 82 86 83 74
Total Noncurrent Assets		 331 313 306 284 278 269 266 259
Long-Term Investments		 30 10 0.00 0.00 0.00 0.00 0.00 0.00
Goodwill		 141 141 141 141 141 141 141 141
Intangible Assets		 59 59 59 59 59 59 59 59
Other Noncurrent Operating Assets		 100 103 106 84 79 69 67 59
Total Liabilities & Shareholders' Equity		 898 747 707 631 681 619 559 445
Total Liabilities		 332 319 352 266 306 279 267 236
Total Current Liabilities		 115 103 112 67 53 51 47 33
Short-Term Debt		 59 57 58 0.00 0.00 0.00 0.00 0.00
Accounts Payable		 3.99 2.33 3.09 9.93 6.10 3.82 2.99 0.99
Accrued Expenses		 15 13 18 19 20 21 15 9.81
Current Employee Benefit Liabilities		 25 17 20 24 14 16 18 9.35
Other Current Liabilities		 12 13 13 13 13 10.00 11 13
Total Noncurrent Liabilities		 217 216 240 199 253 228 220 203
Capital Lease Obligations		 100 102 100 83 93 89 85 78
Other Noncurrent Operating Liabilities		 117 114 140 116 160 140 134 125
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 566 428 355 366 375 340 292 209
Total Preferred & Common Equity		 566 428 355 366 375 340 292 209
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 566 428 355 366 375 340 292 209
Common Stock		 1,547 1,567 1,607 1,616 1,821 1,836 1,848 1,863
Retained Earnings		 -974 -1,137 -1,251 -1,250 -1,446 -1,496 -1,556 -1,654
Accumulated Other Comprehensive Income / (Loss)		 -6.41 -2.14 -0.87 -0.20 -0.02 -0.02 0.05 0.00

Annual Metrics And Ratios for Sana Biotechnology

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -101.02% -23.35% 25.45% -4.28% 3.27%
EBIT Growth		 0.00% -102.61% -24.66% 23.38% -7.30% 5.44%
NOPAT Growth		 0.00% -102.72% -24.73% 23.63% -7.55% 6.97%
Net Income Growth		 0.00% -118.16% -24.75% 24.29% -5.11% 5.82%
EPS Growth		 0.00% 17.84% 90.24% 33.18% -2.10% 20.55%
Operating Cash Flow Growth		 0.00% -61.35% -81.95% -15.53% 12.57% 12.00%
Free Cash Flow Firm Growth		 0.00% 0.00% -61.84% 22.71% 40.35% -20.22%
Invested Capital Growth		 0.00% 0.00% 538.87% 67.03% -19.50% 3.81%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 1.11% 10.37% -0.68% 10.25%
EBIT Q/Q Growth		 0.00% 0.00% 0.64% 9.58% -3.12% 11.28%
NOPAT Q/Q Growth		 0.00% 0.00% 0.57% 9.76% -3.11% 12.72%
Net Income Q/Q Growth		 0.00% 0.00% 0.68% 10.10% -2.78% 12.77%
EPS Q/Q Growth		 0.00% 0.00% 78.23% -13.49% -1.39% 16.55%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -40.64% 10.50% 8.68% 2.10%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 32.41% 4.89% 9.06%
Invested Capital Q/Q Growth		 0.00% 0.00% 1,594.99% 3.53% -4.21% 0.41%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 94.54% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.98% 99.74% 99.81% 98.62% 96.61% 96.22%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -66.09% -61.36% -43.90% -72.00% -99.17%
Cash Return on Invested Capital (CROIC)		 0.00% -2,231.69% -488.83% -163.64% -86.46% -114.34%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 64.47% -16.25% -43.90% -72.00% -99.17%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 67.74% -48.86% -53.97% -98.52% -106.49%
Net Operating Profit after Tax (NOPAT)		 -99 -200 -250 -191 -205 -191
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -41.26% -20.91% -17.65% -38.35% -78.69%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -29.33% -54.23% -57.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -141 -286 -357 -273 -293 -277
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -139 -280 -346 -258 -269 -260
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 4.01 1.51 2.80 1.45
Price to Tangible Book Value (P/TBV)		 0.00 0.00 5.53 2.52 9.17 7.18
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 52.16 18.42 2.21 4.05 1.65
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.21 0.30 0.32 0.33
Long-Term Debt to Equity		 0.00 0.00 0.14 0.19 0.32 0.33
Financial Leverage		 0.00 -0.95 -0.87 -0.73 -0.52 -0.36
Leverage Ratio		 0.00 1.69 1.60 1.59 1.76 1.98
Compound Leverage Factor		 0.00 1.69 1.60 1.57 1.70 1.91
Debt to Total Capital		 0.00% 0.00% 17.37% 23.24% 24.02% 24.58%
Short-Term Debt to Total Capital		 0.00% 0.00% 5.83% 8.51% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 11.54% 14.74% 24.02% 24.58%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 197.56% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -97.56% 82.63% 76.76% 75.98% 75.42%
Debt to EBITDA		 0.00 0.00 -0.44 -0.59 -0.34 -0.31
Net Debt to EBITDA		 0.00 0.00 1.74 1.12 0.44 0.29
Long-Term Debt to EBITDA		 0.00 0.00 -0.29 -0.37 -0.34 -0.31
Debt to NOPAT		 0.00 0.00 -0.61 -0.79 -0.44 -0.43
Net Debt to NOPAT		 0.00 0.00 2.41 1.51 0.58 0.39
Long-Term Debt to NOPAT		 0.00 0.00 -0.41 -0.50 -0.44 -0.43
Altman Z-Score		 0.00 -0.36 2.85 -1.01 -2.97 -5.16
Noncontrolling Interest Sharing Ratio		 0.00% 197.56% 73.51% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.00 12.22 5.62 3.99 3.31 3.54
Quick Ratio		 0.00 12.03 5.55 3.80 3.18 3.36
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -220 -356 -275 -164 -197
Operating Cash Flow to CapEx		 -327.35% -578.01% -840.71% -1,389.39% -1,265.88% -667.52%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 20 126 210 169 176
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 20 106 84 -41 6.46
Enterprise Value (EV)		 0.00 1,028 2,321 464 686 289
Market Capitalization		 588 588 2,923 753 804 364
Book Value per Share		 $0.00 ($32.36) $3.86 $2.62 $1.46 $1.12
Tangible Book Value per Share		 $0.00 ($47.72) $2.80 $1.57 $0.44 $0.23
Total Capital		 0.00 432 882 651 378 332
Total Debt		 0.00 0.00 153 151 91 82
Total Long-Term Debt		 0.00 0.00 102 96 91 82
Net Debt		 0.00 -412 -603 -289 -118 -75
Capital Expenditures (CapEx)		 26 24 30 21 20 33
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -25 -41 -42 -60 -41
Debt-free Net Working Capital (DFNWC)		 0.00 353 510 388 149 115
Net Working Capital (NWC)		 0.00 353 459 333 149 115
Net Nonoperating Expense (NNE)		 32 85 106 79 78 76
Net Nonoperating Obligations (NNO)		 0.00 -412 -603 -289 -118 -75
Total Depreciation and Amortization (D&A)		 1.83 5.92 11 16 25 17
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.14) ($1.43) ($1.46) ($1.16)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 189.54M 188.34M 194.54M 230.89M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.14) ($1.43) ($1.46) ($1.16)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 189.54M 188.34M 194.54M 230.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.14) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 166.43M 191.36M 220.45M 225.02M
Normalized Net Operating Profit after Tax (NOPAT)		 -99 -200 -250 -191 -205 -191
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Sana Biotechnology

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -2.16% 27.68% -182.92% -61.50% 103.19% -1.92% -33.95% 55.69% -2,329.91% 43.25% 56.32%
EBIT Growth		 -3.44% 26.07% -164.42% -59.19% 97.82% -10.44% -31.48% 54.03% -3,228.17% 44.02% 54.50%
NOPAT Growth		 -3.30% 26.50% -165.27% -59.51% 96.38% -10.80% -31.73% 57.54% -1,882.24% 43.87% 54.27%
Net Income Growth		 -2.23% 27.35% -161.14% -57.32% 101.16% -9.54% -30.87% 55.88% -6,189.84% 44.31% 54.05%
EPS Growth		 2.17% -68.00% -152.94% -51.28% 100.00% -4.76% -13.95% 64.41% 0.00% 52.27% 57.14%
Operating Cash Flow Growth		 -28.34% 30.91% -2.01% 17.74% 1.92% 31.69% 17.21% 0.44% 18.46% 9.23% 25.86%
Free Cash Flow Firm Growth		 -289.05% 23.06% 14.78% 83.19% 109.46% 84.19% 95.03% 47.50% -271.47% -87.73% -560.51%
Invested Capital Growth		 2,634.47% 67.03% 132.71% -15.22% -12.99% -19.50% -30.84% -4.92% -0.96% 3.81% 16.55%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -18.72% 5.37% -2.37% -40.42% 102.34% -3,127.66% -34.54% 53.54% -17.84% 22.95% -3.78%
EBIT Q/Q Growth		 -18.04% 4.91% -2.43% -38.45% 98.39% -4,725.29% -21.95% 51.59% -16.84% 18.84% 0.68%
NOPAT Q/Q Growth		 -18.22% 5.10% -2.77% -38.35% 97.32% -2,808.45% -22.19% 55.41% -25.09% 17.64% 0.46%
Net Income Q/Q Growth		 -17.46% 5.49% -2.09% -38.81% 100.86% -9,054.98% -21.97% 53.21% -19.15% 18.11% -0.65%
EPS Q/Q Growth		 -15.38% 6.67% -2.38% -37.21% 100.00% 0.00% -11.36% 57.14% -19.05% 16.00% 0.00%
Operating Cash Flow Q/Q Growth		 9.35% -17.39% -4.21% 25.82% -8.08% 18.24% -26.32% 10.80% 11.48% 8.99% -3.17%
Free Cash Flow Firm Q/Q Growth		 11.74% 44.68% -30.66% 73.64% 149.64% -192.51% 58.93% -178.37% -62.12% -1.28% -44.51%
Invested Capital Q/Q Growth		 -5.16% 3.53% 5.25% -17.96% -2.67% -4.21% -9.58% 12.79% 1.38% 0.41% 1.51%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.06% 100.00% 100.00% 99.95% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.64% 98.03% 97.65% 97.96% -52.40% 97.29% 97.25% 94.01% 95.87% 96.74% 98.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -42.94% -43.90% -56.67% -72.73% -59.15% -72.00% -76.82% -70.51% -92.90% -99.17% -71.44%
Cash Return on Invested Capital (CROIC)		 -386.63% -163.64% -223.45% -113.75% -90.84% -86.46% -83.06% -94.85% -123.33% -114.34% -105.04%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -42.94% -43.90% -56.67% -72.73% -59.15% -72.00% -76.82% -70.51% -92.90% -99.17% -71.44%
Return on Equity Simple (ROE_SIMPLE)		 -52.96% 0.00% -74.76% -101.87% -75.33% 0.00% -82.26% -72.10% -104.56% 0.00% -99.81%
Net Operating Profit after Tax (NOPAT)		 -60 -57 -59 -81 -2.18 -63 -78 -35 -43 -36 -35
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.18% -5.20% -5.73% -10.89% 1.15% -12.13% -13.98% -9.25% -10.90% -13.97% -11.04%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.80% - - - -16.76% - - - -10.72% -12.33%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -86 -82 -84 -116 -1.88 -91 -111 -53 -63 -51 -50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -82 -78 -80 -112 2.62 -79 -107 -50 -58 -45 -47
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.02 1.51 1.46 3.21 2.08 2.80 5.88 3.56 3.16 1.45 1.81
Price to Tangible Book Value (P/TBV)		 3.12 2.52 2.74 7.35 4.59 9.17 12.57 8.65 9.99 7.18 40.84
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.83 2.21 1.89 5.33 3.24 4.05 12.94 6.04 4.61 1.65 1.95
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.28 0.30 0.37 0.45 0.23 0.32 0.25 0.26 0.29 0.33 0.37
Long-Term Debt to Equity		 0.18 0.19 0.24 0.28 0.23 0.32 0.25 0.26 0.29 0.33 0.37
Financial Leverage		 -0.85 -0.73 -0.72 -0.60 -0.59 -0.52 -0.53 -0.49 -0.47 -0.36 -0.43
Leverage Ratio		 1.53 1.59 1.59 1.69 1.64 1.76 1.78 1.91 1.81 1.98 1.93
Compound Leverage Factor		 1.51 1.56 1.55 1.65 -0.86 1.72 1.73 1.79 1.73 1.92 1.89
Debt to Total Capital		 21.96% 23.24% 27.05% 30.89% 18.56% 24.02% 19.85% 20.68% 22.62% 24.58% 27.25%
Short-Term Debt to Total Capital		 8.19% 8.51% 9.75% 11.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 13.77% 14.74% 17.31% 19.51% 18.56% 24.02% 19.85% 20.68% 22.62% 24.58% 27.25%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 78.04% 76.76% 72.95% 69.11% 81.44% 75.98% 80.15% 79.32% 77.38% 75.42% 72.75%
Debt to EBITDA		 -0.55 -0.59 -0.51 -0.45 -0.31 -0.34 -0.31 -0.39 -0.30 -0.31 -0.40
Net Debt to EBITDA		 1.26 1.12 0.67 0.49 0.71 0.44 0.75 0.73 0.41 0.29 0.16
Long-Term Debt to EBITDA		 -0.35 -0.37 -0.33 -0.29 -0.31 -0.34 -0.31 -0.39 -0.30 -0.31 -0.40
Debt to NOPAT		 -0.75 -0.79 -0.70 -0.62 -0.42 -0.44 -0.42 -0.50 -0.39 -0.43 -0.53
Net Debt to NOPAT		 1.72 1.51 0.91 0.67 0.95 0.58 0.99 0.94 0.54 0.39 0.21
Long-Term Debt to NOPAT		 -0.47 -0.50 -0.45 -0.39 -0.42 -0.44 -0.42 -0.50 -0.39 -0.43 -0.53
Altman Z-Score		 0.74 -0.24 -0.90 -0.69 -0.65 -1.79 1.29 -0.66 -1.83 -3.67 -4.40
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.36 3.99 3.60 3.02 4.19 3.31 6.07 5.20 4.47 3.54 3.40
Quick Ratio		 4.23 3.80 3.40 2.91 4.03 3.18 5.88 4.96 4.23 3.36 3.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -256 -142 -185 -49 24 -22 -9.20 -26 -42 -42 -61
Operating Cash Flow to CapEx		 -1,489.56% -1,652.91% -3,643.01% -3,728.66% -2,845.95% -369.92% -414.21% -448.38% -1,266.04% -10,816.74% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 203 210 221 182 177 169 153 173 175 176 178
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 196 84 126 -33 -26 -41 -68 -8.94 -1.70 6.46 25
Enterprise Value (EV)		 779 464 419 968 573 686 1,982 1,042 808 289 347
Market Capitalization		 1,141 753 626 1,141 762 804 2,204 1,209 925 364 378
Book Value per Share		 $2.98 $2.62 $2.24 $1.85 $1.86 $1.46 $1.70 $1.53 $1.31 $1.12 $0.93
Tangible Book Value per Share		 $1.93 $1.57 $1.19 $0.81 $0.84 $0.44 $0.80 $0.63 $0.42 $0.23 $0.04
Total Capital		 725 651 587 514 449 378 468 428 378 332 287
Total Debt		 159 151 159 159 83 91 93 89 85 82 78
Total Long-Term Debt		 100 96 102 100 83 91 93 89 85 82 78
Net Debt		 -363 -289 -207 -173 -189 -118 -222 -167 -117 -75 -31
Capital Expenditures (CapEx)		 4.35 4.60 2.18 1.58 2.23 14 16 13 4.09 0.44 -0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -47 -42 -31 -47 -60 -60 -47 -43 -40 -41 -29
Debt-free Net Working Capital (DFNWC)		 445 388 324 285 213 149 268 213 163 115 80
Net Working Capital (NWC)		 385 333 267 227 213 149 268 213 163 115 80
Net Nonoperating Expense (NNE)		 25 23 23 33 -3.17 25 30 16 17 13 14
Net Nonoperating Obligations (NNO)		 -363 -289 -207 -173 -189 -118 -222 -167 -117 -75 -31
Total Depreciation and Amortization (D&A)		 4.02 4.20 4.35 4.45 4.50 11 3.75 3.90 4.06 5.69 3.65
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.42) ($0.43) ($0.59) $0.00 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21)
Adjusted Weighted Average Basic Shares Outstanding		 189.30M 188.34M 191.23M 192.54M 196.98M 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.42) ($0.43) ($0.59) $0.00 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21)
Adjusted Weighted Average Diluted Shares Outstanding		 189.30M 188.34M 191.23M 192.54M 200.47M 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 190.73M 191.36M 191.50M 196.94M 197.13M 220.45M 221.50M 222.47M 223.27M 225.02M 225.56M
Normalized Net Operating Profit after Tax (NOPAT)		 -60 -57 -59 -81 -1.53 -63 -78 -35 -43 -36 -35
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Below are key takeaways from Sana Biotechnology’s latest results, capturing liquidity, cash flow trends, and ongoing challenges.

  • Strong liquidity position: Q1 2025 current ratio of 3.4 and quick ratio of 3.16 shows ample short-term coverage.
  • Net cash position: Net debt of –$30.6 M, with cash & equivalents and short-term investments totaling $112.7 M.
  • Improving operating cash flow: Q1 2025 outflow of –$48.7 M vs –$65.6 M in Q1 2024, indicating a narrowing cash burn.
  • Reduced net loss: Q1 2025 net loss of –$49.4 M versus –$107.5 M in Q1 2024, reflecting cost control benefits.
  • Investments monetized: Net cash from investing activities was +$16.6 M in Q1 2025, supporting funding needs.
  • No revenue yet: Total revenue remains $0, as product candidates are still in development.
  • Valuation metrics: Market cap of $378 M with book value per share $0.93 (P/B ~1.8×).
  • Persistent losses: NOPAT remains negative (–$35.4 M in Q1 2025), with no path to profitability yet.
  • Negative free cash flow: FCFF of –$60.8 M in Q1 2025 underscores continued cash burn.
  • Altman Z-score of –4.4 in Q1 2025 signals potential financial distress if losses persist.
07/14/25 10:41 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Sana Biotechnology's Financials

When does Sana Biotechnology's financial year end?

According to the most recent income statement we have on file, Sana Biotechnology's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Sana Biotechnology's net income changed over the last 5 years?

Sana Biotechnology's net income appears to be on an upward trend, with a most recent value of -$266.76 million in 2024, rising from -$130.78 million in 2019. The previous period was -$283.26 million in 2023. Find out what analysts predict for Sana Biotechnology in the coming months.

What is Sana Biotechnology's operating income?
Sana Biotechnology's total operating income in 2024 was -$272.72 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $272.72 million
How has Sana Biotechnology's revenue changed over the last 5 years?

Over the last 5 years, Sana Biotechnology's total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Sana Biotechnology have?

Sana Biotechnology's total liabilities were at $250.52 million at the end of 2024, a 9.8% decrease from 2023, and a 16.1% decrease since 2020.

How much cash does Sana Biotechnology have?

In the past 4 years, Sana Biotechnology's cash and equivalents has ranged from $124.81 million in 2020 to $253.03 million in 2021, and is currently $127.57 million as of their latest financial filing in 2024.

How has Sana Biotechnology's book value per share changed over the last 5 years?

Over the last 5 years, Sana Biotechnology's book value per share changed from 0.00 in 2019 to 1.12 in 2024, a change of 112.2%.


Related Companies

This page (NASDAQ:SANA) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
Which Gold Miner Trades at 30% of NAV? The One Buffett Wants
Some of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...
Golden Portfolio | Sponsored
Crypto Is Pumping Again – Now Comes the Real Opportunity
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Trump’s biggest move, misreported
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...
Porter & Company | Sponsored
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsored